microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Publication/Presentation Date
10-1-2019
Abstract
Despite the increased understanding of the oncological mechanisms underlying Glioblastoma multiforme (GBM) pathophysiology, and recent advances in therapeutic strategies such as maximal surgical resection and post-operative radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the prognosis for patients with brain tumors remains limited. Evidences indicate that the assessment of DNA methylation status in cancer stem cells would allow identifying molecules expressed in these cells, to lead to targeted elimination of this critical population from brain tumors, making the glioblastoma treatment more effective. This study aimed to analyze the role of microRNA-181d associated with the methylation status of the O
Volume
1720
First Page
146302
Last Page
146302
ISSN
1872-6240
Published In/Presented At
Lizarte Neto, F. S., Rodrigues, A. R., Trevisan, F. A., de Assis Cirino, M. L., Matias, C. C. M. S., Pereira-da-Silva, G., Peria, F. M., Tirapelli, D. P. D. C., & Carlotti, C. G., Jr (2019). microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide. Brain research, 1720, 146302. https://doi.org/10.1016/j.brainres.2019.146302
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31226325
Department(s)
Administration and Leadership
Document Type
Article